time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the remagus02 study
Clicks: 255
ID: 217890
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
255 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #238 of 353 articles by views in BMC public health
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 353 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Introduction. In non-metastatic breast cancer patients, the REMAGUS02 neoadjuvant study was the first to report a significant impact of circulating tumor cells (CTCs) detection by the CellSearch system on the distant metastasis-free survival (DMFS) and overall survival (OS) endpoints. However, these results were only reported after a short follow-up. Here, we present the updated data, with a longer follow-up. Material and Methods. CTC count was performed before and after neoadjuvant chemotherapy in 118 patients and correlated to survival. Results. CTC count results were available before and/or after neoadjuvant chemotherapy in 115 patients. After a median follow-up of 70 months, detection of ≥1 CTC/7.5 mL before chemotherapy (N=95) was significantly associated with DMFS (P=0.04) and OS (P=0.03), whereas postchemotherapy CTC detection (N=85) had no significant impact. In multivariable analysis, prechemotherapy CTC and triple negative phenotype were the two independent prognostic factors for survival. We observed that the CTC impact is most significant during the first three years of follow-up. Discussion. We confirm that the detection of CTC is independently associated with a significantly worse outcome, but mainly during the first 3-4 years of follow-up. No prognostic impact is seen in patients who are still relapse-free at this moment.
| Reference Key |
bidard2013internationaltime-dependent
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;François-Clément Bidard;Lisa Belin;Suzette Delaloge;Florence Lerebours;Charlotte Ngo;Fabien Reyal;Séverine Alran;Sylvie Giacchetti;Michel Marty;Ronald Lebofsky;Jean-Yves Pierga |
| Journal | BMC public health |
| Year | 2013 |
| DOI |
10.1155/2013/130470
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.